First-line daratumumab shows high efficacy and tolerability even in advanced AL amyloidosis: the real-world experienceBackground: Daratumumab was the first monoclonal CD38 antibody with single-agent activity approved for the treatment of multiple myeloma. Moreover, daratumumab demonstrated high response ...
Carfilzomib in combination with daratumumab in the management of relapsed multiple myeloma. PMID: 33289427 Daratumumab, Elotuzumab, and the Development of Therapeutic Monoclonal Antibodies in Multiple Myeloma. PMID: 27806428 Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multipl...
Carfilzomib in combination with daratumumab in the management of relapsed multiple myeloma. PMID: 33289427 Daratumumab, Elotuzumab, and the Development of Therapeutic Monoclonal Antibodies in Multiple Myeloma. PMID: 27806428 Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multipl...
“Patients are most likely to experience their deepest and most durable responses during the first line of treatment with D-VRd. This regimen has the potential to improve long-term outcomes for newly diagnosed patients and we look forward to working with the FDA on the review of this ...
The mechanism of action of daratumumab in multiple myeloma appears to be via monoclonal antibody binding to CD38-expressing tumor cells resulting in the following: complement-mediated and antibody dependent cell mediated cytotoxicity (ADCC); antibody-dependent cellular phagocytosis; apoptosis via FcR cross...
In the MASTER study (NCT03224507), daratumumab+carfilzomib/lenalidomide/dexamethasone (D-KRd) demonstrated promising efficacy in transplant-eligible newly diagnosed multiple myeloma (NDMM). In GRIFFIN (NCT02874742), daratumumab+lenalidomide/bortezomib/de
Phase II study of daratumumab (DARA)monotherapy in patients with ≥ 3 lines of prior therapyor double refractory multiple myeloma (MM): 54767414MMY2002 (Sirius)。(Abstract No: LBA8512)Session Type:Oral Abstract Session Background: DARA,a human anti-CD38 IgG1κ mAb, has single agent activity...
Daratumumab (Anti-Human CD38) is the first-in-class human-specific anti-CD38 monoclonal antibody (IgG1). Daratumumab has anti-multiple myeloma (MM) effect. Daratumumab impairs MM cell adhesion, which results in an increased sensitivity of MM to proteasome inhibition[1][2]. 体外研究(In Vitro...
Although IV daratumumab has led to better outcomes for many patients with multiple myeloma, Chari described hurdles to administering the infusions. “From a practice management point of view, one of the biggest barriers to getting daratumumab has been that first dose issue, that long infusion, the...
withrelapsedandrefractorymultiplemyelomatreatedwithDARZALEXat 16mg/kginthreeopen-label,clinicaltrials.Themediandurationofexposure was3.3months(range:0.03to20.4months). Seriousadversereactionswerereportedin51(33%)patients.Themost frequentseriousadversereactionswerepneumonia(6%),generalphysical ...